Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

454
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
454
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MCC950-loaded silk microgel-hydrogel composite scaffolds effectively modulate inflammation for improving tissue interaction and remodeling.

Acta biomaterialia·2026
Same author

Compliance modulation of a soft robotic atrioventricular model of heart failure with preserved ejection fraction.

Nature communications·2026
Same author

A Vein Attempt? Experimental Models for Arteriovenous Fistula Research.

Cardiovascular engineering and technology·2026
Same author

Culture Dimensionality Regulates Protein Expression and Bioactivity in THP-1-Derived Macrophages.

Biomedicines·2026
Same author

A Soft Robotic Model for Simulating Heart Valve Disease and Cardiac Interventions.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Intercellular forces driving stratification in a two-layer corneal epithelium: Insight from a Voronoi cell-based simulation model.

PLoS computational biology·2026
Same journal

Metabolic rewiring overcomes physiological constraints in Sphingobium lignivorans SYK-6 for valorization of industrial lignin streams.

Metabolic engineering·2026
Same journal

"Adaptively evolved chitin overproduction in Saccharomyces cerevisiae".

Metabolic engineering·2026
Same journal

Programmable and controllable sexual life cycle for improved evolution in Komegataella phaffii.

Metabolic engineering·2026
Same journal

Evolution-guided high yield production of potent Gα<sub>q/11</sub>-signalling inhibitors FR900359 and YM-254890.

Metabolic engineering·2026
Same journal

Engineering a microbial platform for the biosynthesis of anthranilic acid and its derivatives.

Metabolic engineering·2026
Same journal

Metabolic engineering strategies for producing decanoic acid and related oleochemicals: 1-decanol, 2-nonanone, and poly(3-hydroxydecanoate) in Escherichia coli.

Metabolic engineering·2026
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K

Bioengineered human heparin with anticoagulant activity.

Megan S Lord1, Bill Cheng1, Fengying Tang1

  • 1Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052, Australia.

Metabolic Engineering
|July 23, 2016
PubMed
Summary
This summary is machine-generated.

Researchers bioengineered human heparin-like heparan sulfate using recombinant serglycin. This novel compound shows anticoagulant activity, suggesting a potential safe, next-generation pharmaceutical alternative to traditional heparin.

Keywords:
GlycosaminoglycanHeparinProteoglycanRecombinant expressionSerglycin

More Related Videos

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

8.1K
Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating
05:35

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Published on: June 23, 2018

7.8K

Related Experiment Videos

Last Updated: Mar 17, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

8.1K
Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating
05:35

Surface Engineering of Pancreatic Islets with a Heparinized StarPEG Nanocoating

Published on: June 23, 2018

7.8K

Area of Science:

  • Biochemistry
  • Biotechnology
  • Pharmacology

Background:

  • Heparin is a crucial carbohydrate anticoagulant for preventing thrombosis.
  • Impurities in current heparin sources can compromise its clinical efficacy and safety.
  • Development of alternative, well-defined heparin sources is clinically significant.

Purpose of the Study:

  • To bioengineer heparin-like heparan sulfate.
  • To assess the anticoagulant properties of the bioengineered product.
  • To explore its potential as a next-generation pharmaceutical heparin.

Main Methods:

  • Recombinant expression of human serglycin in human cells.
  • Characterization of glycosaminoglycan chain decoration (heparan sulfate, chondroitin/dermatan sulfate).
  • Culturing cells under varying glucose concentrations (e.g., 25mM) to modulate glycosaminoglycan composition.
  • Assay of anticoagulant activity compared to porcine unfractionated heparin.

Main Results:

  • Successfully produced heparin-like heparan sulfate via recombinant human serglycin.
  • Observed decoration with both heparan sulfate and chondroitin/dermatan sulfate chains.
  • Demonstrated that glucose concentration influences glycosaminoglycan chain abundance.
  • Recombinant serglycin produced with 25mM glucose exhibited significant anticoagulant activity, approximately one-seventh of porcine unfractionated heparin.

Conclusions:

  • Bioengineered human heparin-like heparan sulfate is achievable.
  • The anticoagulant activity suggests potential therapeutic applications.
  • This approach offers a promising route to a safer, next-generation pharmaceutical heparin alternative.